Safety and immunogenicity of inactivated SARS-CoV-2 vaccine in high-risk occupational population: a randomized, parallel, controlled clinical trial

被引：0

作者：

Yongliang Feng

Jing Chen

Tian Yao

Yue Chang

Xiaoqing Li

Rongqin Xing

Hong Li

Ruixue Xie

Xiaohong Zhang

Zhiyun Wei

Shengcai Mu

Ling Liu

Lizhong Feng

Suping Wang

机构：

[1] Shanxi Medical University,Department of Epidemiology, School of Public Health

[2] Shanxi Medical University,Center of Clinical Epidemiology and Evidence Based Medicine

[3] Shanxi Provincial Center for Disease Control and Prevention,undefined

[4] Shanxi Provincial Key Laboratory for Major Infectious Disease Response,undefined

[5] Outpatient Department of Shanxi Aviation Industry Group Co. LTD,undefined

来源：

Infectious Diseases of Poverty | / 10卷

关键词：

COVID-19; Inactivated SARS-CoV-2 vaccine; Immunogenicity; Safety; High-risk occupational population; Randomized controlled trial;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

共 50 条

[41] Self-Reported Allergic Adverse Events Following Inactivated SARS-CoV-2 Vaccine (TURKOVAC™) among General and High-Risk Population
Kara, Ates
Coskun, Aslihan
Temel, Fehminaz
Ozelci, Pervin
Topal, Selmur
Ates, Ihsan
VACCINES, 2023, 11 (02)
[42] Immunogenicity and safety of SARS-CoV-2 recombinant protein subunit vaccine (IndoVac) adjuvanted with alum and CpG 1018 in Indonesian adults: A phase 3, randomized, active-controlled, multicenter trial
Nurdin, Asrawati
Nency, Yetty Movieta
Maddeppungeng, Martira
Sekartini, Rini
Sari, Rini Mulia
Surachman, Fikrianti
Yani, Finny Fitry
Raveinal
Anggrainy, Fenty
Hafiz, Al
Linosefa
Machmud, Rizanda
Deza, Putri Awaliyah
Rujiana, Vovinda
Rahimi, Martga Bella
Farhanah, Nur
Pramudo, Setyo Gundi
Hapsari, Rebriarina
Anantyo, Dimas Tri
Mulyono
Mahati, Endang
Maharani, Nani
Darma, Sidrah
Darussalam, Andi Husni Esa
Shakinah, Sharifah
Massi, Muhammad Nasrum
Soedjatmika
VACCINE, 2024, 42 (12) : 3009 - 3017
[43] Hydroxychloroquine with or without azithromycin for treatment of early SARS-CoV-2 infection among high-risk outpatient adults: A randomized clinical trial
Johnston, Christine
Brown, Elizabeth R.
Stewart, Jenell
Karita, Helen C. Stankiewicz
Kissinger, Patricia J.
Dwyer, John
Hosek, Sybil
Oyedele, Temitope
Paasche-Orlow, Michael K.
Paolino, Kristopher
Heller, Kate B.
Leingang, Hannah
Haugen, Harald S.
Dong, Tracy Q.
Bershteyn, Anna
Sridhar, Arun R.
Poole, Jeanne
Noseworthy, Peter A.
Ackerman, Michael J.
Morrison, Susan
Greninger, Alexander L.
Huang, Meei-Li
Jerome, Keith R.
Wener, Mark H.
Wald, Anna
Schiffer, Joshua T.
Celum, Connie
Chu, Helen Y.
Barnabas, Ruanne, V
Baeten, Jared M.
ECLINICALMEDICINE, 2021, 33
[44] Immunogenicity, safety and clinical outcomes of the SARS-CoV-2 BNT162b2 vaccine in adolescents with type 1 diabetes
Emeksiz, Hamdi Cihan
Hepokur, Merve Nur
Sahin, Sibel Ergin
Sirvan, Banu Nursoy
Cicek, Burcin
Onder, Asan
Yildiz, Metin
Aksakal, Derya Karaman
Bideci, Aysun
Ovali, Husnu Fahri
Isman, Ferruh
FRONTIERS IN PEDIATRICS, 2023, 11
[45] Safety and immunogenicity of the third (booster) dose of inactivated and recombinant protein SARS-CoV-2 vaccine for patients with endocrine-related cancer
Han, Shanshan
Yang, Yuping
Wang, Tingrui
Song, Rui
Hu, Daixing
Peng, Mingli
Lin, Zijing
Deng, Qin
Ren, Hong
Ming, Jia
FRONTIERS IN PUBLIC HEALTH, 2023, 11
[46] Safety of SARS-CoV-2 vaccines: a systematic review and meta-analysis of randomized controlled trials
Chen, Musha
Yuan, Yue
Zhou, Yiguo
Deng, Zhaomin
Zhao, Jin
Feng, Fengling
Zou, Huachun
Sun, Caijun
INFECTIOUS DISEASES OF POVERTY, 2021, 10 (01)
[47] Safety and immunogenicity of an egg-based inactivated Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Interim results of a randomized, placebo-controlled, phase 1/2 trial in Vietnam
Anh Duc Dang
Thiem Dinh Vu
Ha Hai Vu
Van Thanh Ta
Anh Thi Van Pham
Mai Thi Ngoc Dang
Be Van Le
Thai Huu Duong
Duoc Van Nguyen
Lawpoolsri, Saranath
Chinwangso, Pailinrut
McLellan, Jason S.
Hsieh, Ching-Lin
Garcia-Sastre, Adolfo
Palese, Peter
Sun, Weina
Martinez, Jose L.
Gonzalez-Dominguez, Irene
Slamanig, Stefan
Carreno, Juan Manuel
Tcheou, Johnstone
Krammer, Florian
Raskin, Ariel
Huong Minh Vu
Thang Cong Tran
Huong Mai Nguyen
Mercer, Laina D.
Raghunandan, Rama
Lal, Manjari
White, Jessica A.
Hjorth, Richard
Innis, Bruce L.
Scharf, Rami
VACCINE, 2022, 40 (26) : 3621 - 3632
[48] Immunogenicity and Protective Efficacy of Psoralen-Inactivated SARS-CoV-2 Vaccine in Nonhuman Primates
Sanders, John W.
Ewing, Daniel
Sundaram, Appavu K.
Gamble, Christopher Scott
Blevins, Maria
Liang, Zhaodong
Sanders, Leigh Ann
Ornelles, David A.
Sun, Peifang
Lenart, Klara
Feuerstein, Hendrik
Lore, Karin
Petrovsky, Nikolai
Williams, Maya
Porter, Kevin R.
VACCINES, 2024, 12 (05)
[49] Immunogenicity and safety of SpikoGen®, an adjuvanted recombinant SARS-CoV-2 spike protein vaccine as a homologous and heterologous booster vaccination: A randomized placebo-controlled trial
Tabarsi, Payam
Anjidani, Nassim
Shahpari, Ramin
Roshanzamir, Khashayar
Fallah, Newsha
Andre, Greiciely
Petrovsky, Nikolai
Barati, Saghar
IMMUNOLOGY, 2022, 167 (03) : 340 - 353
[50] Immunogenicity and safety of a SARS-CoV-2 inactivated vaccine (CoronaVac) co-administered with an inactivated quadrivalent influenza vaccine: A randomized, open-label, controlled study in healthy adults aged 18 to 59 years in China
Shenyu, Wang
Xiaoqian, Duan
Bo, Chen
Xuan, Deng
Zeng, Wang
Hangjie, Zhang
Qianhui, Zheng
Zhenzhen, Liang
Chuanfu, Yan
Juan, Yang
Gang, Zeng
Huakun, Lv
VACCINE, 2022, 40 (36) : 5356 - 5365

← 1 2 3 4 5 →